+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Risk of valvular heart disease after treatment for Hodgkin lymphoma



Risk of valvular heart disease after treatment for Hodgkin lymphoma



Journal of the National Cancer Institute 107(4):



Hodgkin lymphoma (HL) survivors are at increased risk of developing valvular heart disease (VHD). We evaluated the determinants of the risk and the radiation dose-response. A case-control study was nested in a cohort of 1852 five-year HL survivors diagnosed at ages 15 to 41 years and treated between 1965 and 1995. Case patients had VHD of at least moderate severity as their first cardiovascular diagnosis following HL treatment. Control patients were matched to case patients for age, gender, and HL diagnosis date. Treatment and follow-up data were abstracted from medical records. Radiation doses to heart valves were estimated by reconstruction of individual treatments on representative computed tomography datasets. All statistical tests were two-sided. Eighty-nine case patients with VHD were identified (66 severe or life-threatening) and 200 control patients. Aortic (n = 63) and mitral valves (n = 42) were most frequently affected. Risks increased more than linearly with radiation dose. For doses to the affected valve(s) of less than or equal to 30, 31-35, 36-40, and more than 40 Gy, VHD rates increased by factors of 1.4, 3.1, 5.4, and 11.8, respectively (P trend < .001). Approximate 30-year cumulative risks were 3.0%, 6.4%, 9.3%, and 12.4% for the same dose categories. VHD rate increased with splenectomy by a factor of 2.3 (P = .02). Radiation dose to the heart valves can increase the risk of clinically significant VHD, especially at doses above 30 Gy. However, for patients with mediastinal involvement treated today with 20 or 30 Gy, the 30-year risk will be increased by only about 1.4%. These findings may be useful for patients and doctors both before treatment and during follow-up.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058781184

Download citation: RISBibTeXText

PMID: 25713164

DOI: 10.1093/jnci/djv008


Related references

The risk of non-Hodgkin's lymphoma after Hodgkin's disease, with special reference to splenic treatment. Haematologica 83(7): 636-644, 1998

ESC Working Group on Valvular Heart Disease Position Paper: assessing the risk of interventions in patients with valvular heart disease. European Heart Journal 33(7): 822-8, 828a, 828b, 2012

Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: incidence, treatment, and prognosis. Journal of Clinical Oncology 19(7): 2026-2032, 2001

Valvular Heart Disease: Current Treatment and Future Perspectives. Topics: I. Diagnosis; 2. Recent progress in echocardiography for valvular heart disease. Nihon Naika Gakkai Zasshi. Journal of the Japanese Society of Internal Medicine 105(2): 192-198, 2016

Valvular Heart Disease: Current Treatment and Future Perspectives. Topics: I. Diagnosis; 1. Physical examination for valvular heart disease. Nihon Naika Gakkai Zasshi. Journal of the Japanese Society of Internal Medicine 105(2): 184-191, 2016

Risk-adjusted prognostic models for Hodgkin's disease (HD) and grade II non-Hodgkin's lymphoma (NHL II): Validation on 6728 British National Lymphoma Investigation patients. British Journal of Haematology 120(2): 277-280, 2003

Dosimetric predictors of asymptomatic heart valvular dysfunction following mediastinal irradiation for Hodgkin's lymphoma. RadioTherapy and Oncology 101(2): 316-321, 2011

Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma. Journal of Clinical Oncology 34(24): 2940-2941, 2016

Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Internal Medicine 175(6): 1007-1017, 2015

Coronary Heart Disease After Mediastinal Radiotherapy for Hodgkin Lymphoma: Can Risk Calculations From Historic Cohorts Be Used Today?. Journal of Clinical Oncology 34(24): 2939-2940, 2016

Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease. Quarterly Journal of Nuclear Medicine 45(3): 269-273, 2001

Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology 23(30): 7555-7564, 2005

Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment. Hematology. American Society of Hematology. Education Program 2016(1): 323-330, 2016

Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood 107(7): 2912-2919, 2006